Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.

ABSTRACT:

Background

Cytopenia is a common complication in patients with myelofibrosis and may worsen during treatment with ruxolitinib.

Methods

The RUX-MF multicenter study evaluated 879 patients treated with ruxolitinib for at least 6 months, categorizing them into four groups based on the evolution of cytopenia: never cytopenic, treatment-emergent cytopenia, persistent cytopenia, and improved anemia.

Results

At baseline, 40.6% of patients presented with cytopenia, increasing to 57.8% after 6 months. Baseline cytopenia was associated with significantly reduced median overall survival (OS) compared to noncytopenic patients (3.7 vs. 6.7 years). Prognosis varied notably across groups: patients who remained noncytopenic had the median best OS (8.1 years), whereas those with persi

SUBMITTER: Palandri F 

PROVIDER: S-EPMC12904337 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature